Menu Search
Equities

Lyell Immunopharma Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LYEL:NSQ

Lyell Immunopharma Inc

Actions
  • Price (USD)23.33
  • Today's Change-0.77 / -3.20%
  • Shares traded45.08k
  • 1 Year change+76.37%
  • Beta-0.1499
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 26-Feb-26
Select bar for recommendation details.
Recommendations26-Feb-26
Buy0
Outperform2
Hold0
Sell1
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Lyell Immunopharma Inc have a median target of 38.50, with a high estimate of 45.00 and a low estimate of 32.00. The median estimate represents a 59.75% increase from the last price of 24.10.
High86.7%45.00
Med59.8%38.50
Low32.8%32.00

Earnings history & estimates in USD

On Nov 12, 2025, Lyell Immunopharma Inc reported 3rd quarter 2025 losses of -2.13 per share. This result exceeded the -2.64 consensus loss of the 4 analysts covering the company and exceeded last year's 3rd quarter results by 37.35%.
The next earnings announcement is expected on Mar 09, 2026.
Average growth rate+9.63%
Lyell Immunopharma Inc reported annual 2024 losses of -15.60 per share on Mar 11, 2025.
Average growth rate+14.44%
More ▼

Revenue history & estimates in USD

Lyell Immunopharma Inc had 3rd quarter 2025 revenues of 15.00k. None of the 3 analysts following the company expected it to generate revenues. This was 400.00% above the prior year's 3rd quarter results.
Average growth rate-0.56%
Lyell Immunopharma Inc had revenues for the full year 2024 of 61.00k. This was 53.08% below the prior year's results.
Average growth rate+180.74%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.